Comparative Evaluation of Microultrafiltration Devices for Determination of Protein Binding

Ohshima, Taeyuki; Johno, Ikuo; Kitazawa, Shigeru

doi:10.1097/00007691-198803000-00013

Cited by 19 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein binding of phenytoin was evaluated by ultrafiltration with a commercially available MPS‐3 device (Amicon, Tokyo, Japan) under current laboratory routine conditions (25±3 °C) ( 19). All serum samples were ultrafiltered as soon as possible after separation from blood, because pH change affects the serum protein binding of drugs ( 20).…”

Section: Introductionmentioning

confidence: 99%

Serum protein binding kinetics of phenytoin in monotherapy patients

Kodama

Shinozawa

et al. 1998

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Serum protein binding kinetics of phenytoin in monotherapy patients

Kodama

Shinozawa

et al. 1998

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…The extent of CIX binding to plasma proteins was determined on day 1 with an ultrafiltration system. The Ultrafree CL device (UFC4LG25; Millipore, Saint-Quentin-en Yvelines, France) was used (18). In brief, 1 ml of the plasma sample was placed in the filter cup (upper part of the device), which is separated from the filtrate cup by an ultrafiltration membrane.…”

mentioning

confidence: 99%

Pharmacokinetics and protein binding of ceftriaxone during pregnancy

Bourget

Fernandez

Quinquis

et al. 1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The purpose of the present work was to study the pharmacokinetics and the protein binding (free fraction of the drug) of ceftriaxone (CTX) during pregnancy. Nine pregnant women (ages, 20 to 34 years) whose gestational ages ranged from 28 4/7 to 40 5/7 weeks were included. The diagnosis of infection was established in all cases; i.e., four women had chorioamnionitis and five women had pyelonephritis. The following triple antibiotic therapy was infused with the aim of achieving cure: CTX, 2 g once every 24 h (constant rate over 60 min); tobramycin, 3 mg/kg of body weight once every 24 h; and ornidazole, 1 g/day. Two series of blood samples were collected, i.e., during the first day of treatment (on day 1), to establish the primary pharmacokinetic profile of CTX, and at the plateau (on day 7), to evaluate a possible accumulation of the drug.This was an open, noncompartmental study, with each patient serving as her own control. Concentrations of total and unbound CTX in serum were measured by a high-performance liquid chromatographic method. Pharmacokinetic analysis was done by a noncompartmental method. Data were compared by a Wilcoxon t test (a P value of .0.05 was considered significant). Data were also compared with those obtained for healthy subjects who received similar treatments. (i) The tolerance to treatment was excellent, and in all cases patients had a complete remission without premature delivery. (ii) No accumulation of CTX was noted during the treatment, and the profiles of the drug determined at days 1 and 7 were not significantly different. (iii) The pharmacokinetic parameters measured in pregnant patients during the third trimester of pregnancy were similar to those measured in healthy subjects. (iv) Residual concentrations of total and unbound CTX measured at 24 h were greater than the MICs for allegedly susceptible organisms, both on day 1 and at steady state. (v) During the final 3 months of pregnancy, the dosage schedule of CTX (2-g infusion per day) required no particular adjustment (i.e., neither a loading dose nor any increase in the maintenance dose).Ceftriaxone (CTX) is the first broad-spectrum cephalosporin prescribed on a single-daily-administration basis (24). This dosage schedule, which is unusual for a beta-lactam antibiotic, has been validated by a number of clinical studies since CTX came onto the market (11, 31). A pharmacodynamic and bacteriological approach taken together with the specific pharmacokinetics of the compound have formed the theoretical basis of a simplified administration schedule compared with those for other beta-lactams with shorter half-lives (9). The dosage recommended by the manufacturer (a single injection of 1 to 2 g every 24 h) is the consequence of an essential peculiarity of CTX: its prolonged terminal half-life (between 6.5 and 8.5 h) (21). The antibacterial spectrum of CTX is similar to that of other broad-spectrum cephalosporins. However, in comparison with other members of the group, it is less active against anaerobic organisms such as Bacteroides fr...

show abstract

“…7,11) The FF values of drugs obtained by UFC and CCW showed significantly different values compared to the control value. From leakage and adsorption studies, it is suggested that the difference of the FF value of these two devices was dependent on the protein leakage and the adsorption to the device.…”

Section: Resultsmentioning

confidence: 90%